Astellas Pharma, Inc. (ALPMF)
14.60
+1.06
(+7.79%)
USD |
OTCM |
Jun 18, 16:00
Astellas Pharma Revenue (TTM) : 14.19B for March 31, 2026
Revenue (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 14.19B |
| December 31, 2025 | 13.78B |
| September 30, 2025 | 13.46B |
| June 30, 2025 | 13.01B |
| March 31, 2025 | 12.54B |
| December 31, 2024 | 12.32B |
| September 30, 2024 | 11.78B |
| June 30, 2024 | 11.39B |
| March 31, 2024 | 11.08B |
| December 31, 2023 | 10.97B |
| September 30, 2023 | 10.96B |
| June 30, 2023 | 11.00B |
| March 31, 2023 | 11.21B |
| December 31, 2022 | 11.15B |
| September 30, 2022 | 11.30B |
| June 30, 2022 | 11.51B |
| March 31, 2022 | 11.55B |
| December 31, 2021 | 11.84B |
| September 30, 2021 | 11.96B |
| June 30, 2021 | 11.91B |
| March 31, 2021 | 11.78B |
| December 31, 2020 | 11.74B |
| September 30, 2020 | 11.74B |
| June 30, 2020 | 11.78B |
| March 31, 2020 | 11.96B |
| Date | Value |
|---|---|
| December 31, 2019 | 11.83B |
| September 30, 2019 | 11.90B |
| June 30, 2019 | 11.80B |
| March 31, 2019 | 11.78B |
| December 31, 2018 | 11.82B |
| September 30, 2018 | 11.83B |
| June 30, 2018 | 11.84B |
| March 31, 2018 | 11.73B |
| December 31, 2017 | 11.64B |
| September 30, 2017 | 11.69B |
| June 30, 2017 | 11.90B |
| March 31, 2017 | 12.12B |
| December 31, 2016 | 12.09B |
| September 30, 2016 | 11.98B |
| June 30, 2016 | 11.72B |
| March 31, 2016 | 11.42B |
| December 31, 2015 | 11.23B |
| September 30, 2015 | 11.25B |
| June 30, 2015 | 11.31B |
| March 31, 2015 | 11.37B |
| December 31, 2014 | 12.19B |
| September 30, 2014 | 11.90B |
| June 30, 2014 | 11.82B |
| December 31, 2013 | 11.64B |
| September 30, 2013 | 11.78B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Revenue (TTM) Benchmarks
| Daiichi Sankyo Co., Ltd. | 14.06B |
| Takeda Pharmaceutical Co., Ltd. | 29.91B |
| Eisai Co., Ltd. | 5.477B |
| Chugai Pharmaceutical Co., Ltd. | 8.564B |
| Santen Pharmaceutical Co., Ltd. | 1.933B |